Evidence map›Paper›PMID 29563072›Full record

Trial reportBiochimica et biophysica acta. Proteins and proteomics2018

d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study.

Basant Pradhan, Ludmil Mitrev, Ruin Moaddell, Irving W Wainer

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biochimica et biophysica acta. Proteins and proteomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04771767 (Assessing a Combined Ketamine and Online Cognitive Behavioural Therapy Intervention for Treatment Resistant Post-Traumatic Stress Disorder), which is not on this map. Cited by 32 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 9 pooled it
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04771767 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Assessing a Combined Ketamine and Online Cognitive Behavioural Therapy Intervention for Treatment Resistant Post-Traumatic Stress Disorder

TypeinterventionalSponsorQueen's UniversityRan2021 to 2024Enrolled16ConditionsPost-Traumatic Stress DisorderArmsKetamine, Online Trauma-Focused Cognitive Behavioural Therapy
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 9 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: A systematic review and meta-analysis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Basant PradhanDepartment of Psychiatry, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, NJ, USA.
Ludmil MitrevDepartment of Psychiatry, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, NJ, USA.
Ruin MoaddellBio-analytical Chemistry and Drug Discovery Section of the National Institute on Aging (NIA), National Institute of Health (NIH), Bethesda, MD, USA.
Irving W WainerDepartment of Anesthesiology, Cooper University Hospital and Cooper Medical School of Rowan University, Camden, NJ, USA. Electronic address: iwwainer@gmail.com.
Cooper University Hospital · USCooper Medical School of Rowan University · USNational Institute on Aging · US

Funding

Brain and Behavior Research Foundation 24120Intramural NIH HHS Z99 AG999999
6 · The paper itself

Abstract

Post-traumatic stress disorder (PTSD) is a chronic and debilitating condition that is often refractory to standard frontline antidepressant therapy. A promising new approach to PTSD therapy is administration of a single sub-anesthetic dose of (R,S)-ketamine (Ket). The treatment produces rapid and significant therapeutic response, which lasts for only 4-7 days. In one of our studies, the mean duration of response was increased to 33 days when Ket administration was combined with a mindfulness-based cognitive therapy, Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER). We now report the results from a 20-patient study, which examined the duration of sustained response with combined TIMBER-Ket therapy, TIMBER-K arm, relative to the response observed in a placebo-controlled arm, TIMBER-P. A significant difference in the duration of response was observed between TIMBER-K and TIMBER-P arms: 34.44 ± 19.12 days and 16.50 ± 11.39 days, respectively (p = 0.022). Previous studies identified a negative correlation between antidepressant response to Ket and basal plasma concentrations of d-serine (DSR). In this study, the basal DSR levels positively correlated with the pre-treatment severity of PTSD symptoms (Pearson's r = 0.42, p = 0.07) and patients with basal DSR level ≥ 3.5 μM displayed not only higher PTSD severity but also shorter duration of response. The data indicate that basal DSR levels may serve as a biomarker of the severity of PTSD symptoms and as a predictor of clinical response. This article is part of a Special Issue entitled: d-Amino acids: biology in the mirror, edited by Dr. Loredano Pollegioni, Dr. Jean-Pierre Mothet and Dr. Molla Gianluca.

Indexed as

MindfulnessAdultBiomarkersDouble-Blind MethodFemaleHumansKetamineMaleMiddle AgedPilot ProjectsSerineStress Disorders, Post-TraumaticBiomarkersKetamineSerined-SerineKetamineMindfulnessPTSD

Identifiers

PMID29563072
PMCPMC9067607
OpenAlexW2791247764

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.